In ESCC patients, the proportions of CD3-CD16+ NK cells (8.81 ± 0.73%, p = 0.042) and CD3-CD16+CD56+ NK cells (4.76 ± 0.67%, p = 0.012) were significantly reduced, whereas the proportion of CD3-CD56+ NK cells was significantly increased to 14.18 ± 1.02% (p = 0.016), as shown in Supplementary Figure S2b. The gene discussed is NCAM1; the disease is esophageal squamous cell carcinoma.